Clik here to view.
BeiGene Appoints Chan Lee as General Counsel
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative...
View ArticleClik here to view.
BeiGene Provides Regulatory Update on the U.S. Biologics License Application...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable...
View ArticleClik here to view.
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for...
LITTLETON, Colo. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods Administration for multiple indications to...
View ArticleClik here to view.
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China and US-based global biopharmaceutical company committed to the research, development and commercialization...
View ArticleClik here to view.
Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment...
View ArticleClik here to view.
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients...
View ArticleClik here to view.
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event
COLLEGE STATION, Texas Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene...
View ArticleClik here to view.
Ozgene and Gen-H partner on Ozgene’s new OzBIG targeted humanization capability
PERTH, Australia & HEIDELBERG, Germany Ozgene and Gen-H are pleased to announce our working partnership supporting Ozgene’s new OzBIG capability. Ozgene Pty Ltd is a privately held CRO based in...
View ArticleClik here to view.
InnoCare Announces First Prescription of Tafasitamab in Combination with...
BEIJING InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan...
View ArticleClik here to view.
随机对照研究发现Masimo SedLine®脑功能监护仪能帮助引导儿童小型手术的麻醉
瑞士纳沙泰尔 (美国商业资讯)– Masimo (NASDAQ: MASI)今天宣布《临床麻醉杂志》发表的一项随机对照试验的结果。在该试验中，新加坡竹脚妇幼医院的Melody H.Y. Long博士及其同事评估采用Masimo...
View ArticleClik here to view.
デンタル・モニタリング：7月の製品発表
米テキサス州オースティン & パリ （ビジネスワイヤ） — デンタル・モニタリングは、歯科専門家と業界パートナーのために画期的なサービスを開始しました。DMインテリジェント・プラットフォームは、現在市販されているすべての歯科デジタルソリューションと連携・統合できる唯一のデジタルワークフローとなりました。...
View ArticleClik here to view.
Neuraptive...
费城 (美国商业资讯)–Neuraptive Therapeutics, Inc. (Neuraptive)是一家临床阶段生物技术公司，致力于开发治疗周围神经损伤(PNI)的新型疗法和医疗产品。该公司今天宣布，其2a期临床试验已招募到首位患者。该试验旨在评估NTX-001在治疗和预防面瘫方面相比标准护理的安全性和有效性。 Neuraptive执行副总裁兼研发主管Evan...
View ArticleClik here to view.
ニューラプティブ・セラピューティクス、顔面神経まひを予防するためのNTX-001の第2相臨床試験で初の患者登録を発表、外傷による末梢神経損傷におけるNTX...
フィラデルフィア （ビジネスワイヤ） — 末梢神経損傷（PNI）治療のための新規の治療薬や医療製品の開発に専心する臨床段階のバイオテクノロジー企業であるニューラプティブ・セラピューティクス（ニューラプティブ）は本日、顔面神経まひの治療と予防において、標準治療と比較してNTX-001の安全性と有効性を評価する第2a相臨床試験で初の患者登録を行ったと発表しました。...
View ArticleClik here to view.
joimax® Expands Distribution in China
KARLSRUHE, Germany German-based joimax®, the market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, and distributor Andeller (Nanjing)...
View ArticleClik here to view.
joimax® 扩展其中国经销
德国卡尔斯鲁厄的 总部位于德国卡尔斯鲁厄的joimax® 是全内窥镜和微创脊柱手术技术和培训方法的市场领导者. joimax®与其中国总代理, 建发集团旗下子公司, 南京建尔发医疗科技有限公司很高兴能够宣布他们在中国市场的独家合作伙伴关系。此合作关系立即生效。 南京建尔发医疗科技有限公司取代上海懋煜医疗器械有限公司。 今年早些时候，joimax®...
View ArticleClik here to view.
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the...
View ArticleClik here to view.
Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation...
ENGLEWOOD CLIFFS, N.J. Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS)...
View ArticleClik here to view.
Masimo SedLine®脳機能モニタリングが小手術を受ける小児で麻酔の指針として役立つことを示すランダム化対照試験
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、Journal of Clinical Anesthesia誌に掲載されたランダム化対照試験の結果を発表しました。試験でシンガポールのKK婦人科・小児科病院のメロディ・H・Y・ロング医師と同僚らは、Masimo...
View ArticleClik here to view.
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase...
View Article